List Biological Laboratories

What List Biological Laboratories does

List Biological Laboratories (List Labs) is a privately held microbial Contract Development and Manufacturing Organization (CDMO) founded in 1978 in Campbell, California. The company specializes in bacterial fermentation and the contract manufacturing of bacterial-based drug substance and drug product, with particular focus on live biotherapeutic products (LBPs), bacterial toxins, polysaccharides, and recombinant proteins. Its customers include large pharmaceutical companies, biotechnology firms developing microbiome-based therapeutics, early-stage clinical biotechs, and academic and government research organizations, served across the United States with distributor-led reach into Europe and Asia-Pacific.

List Labs' technology platform centers on bacterial fermentation, including proprietary handling of strict anaerobes and spore-forming organisms, downstream purification, and lyophilization. It operates a research reagent and process development site at its Campbell headquarters and a 26,000-square-foot cGMP manufacturing facility in Fishers, Indiana, through its wholly-owned subsidiary List Biotherapeutics, with an announced expansion to a 110,000-square-foot facility. The product portfolio spans nearly 100 research reagent SKUs (toxins, toxoids, FRET peptides/SNAPtide, vaccine carrier proteins, antibodies, lipopolysaccharides) and CDMO services covering process development, cGMP Phase I and II manufacturing, and QC analytical testing. Regulatory credentials include a California Drug Manufacturing License, compliance with 21 CFR 210/211 and ICH guidelines, and multiple Drug Master Files held with FDA and Health Canada that support client IND and IMPD filings. Intellectual property includes a granted SNAPtide patent (US 6,504,006) and a pending provisional application.

The business operates through two revenue streams: (1) professional-services contract manufacturing for clinical-phase bacterial and LBP drug programs, priced on a per-engagement basis with enterprise pharmaceutical and biotech customers including BetterLife Pharma (interferon alpha 2b), Scioto Biosciences (LBP development), and Altum Pharma; and (2) catalog reagent sales via direct e-commerce with volume-based pricing starting at a $7,500 minimum purchase threshold, supplemented by distributor relationships in Austria, the broader EMEA region, South Korea, Singapore, and China. In 2021, South Korean clinical-stage biotech Genome & Company (KOSDAQ: 314130) acquired a controlling interest, forming an integrated global Live Biotherapeutic Drug Development platform; List Labs retained independent operational control of all client activities. Post-acquisition, List Biotherapeutics announced a more than $125 million facility investment and the planned hiring of 210 employees to scale commercial-stage clinical manufacturing capacity.

Name

List Biological Laboratories

Legal name

List Biological Laboratories, Inc.

Website

https://www.listlabs.com

Company type

Private

Founded year

1978

Operating status

Operating

Headcount range

11–50 employees

Short description

List Biological Laboratories is a microbial CDMO that manufactures bacterial toxins, polysaccharides, recombinant proteins, and live biotherapeutic products for clinical-phase pharmaceutical, biotech, and academic research customers across the U.S., Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Microbial CDMO Services (Bacterial Biologics Contract Manufacturing)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industry

Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Microbial CDMO services
• Live biotherapeutic manufacturing
• Bacterial toxin production
• GMP contract manufacturing
• Research reagent products

Headquarters

HQ city

Campbell

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Contract Manufacturing Services: CDMO services for clinical-phase live biotherapeutic products and microbiome therapeutics. Provides end-to-end manufacturing from fermentation through lyophilization for bacterial-based products.
2. Product Sales: Sale of manufactured bacterial products and reagent products to pharmaceutical and biotech customers.
3. Custom Services: Custom development and manufacturing services tailored to specific client requirements for live biotherapeutic products.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

List Labs is a microbial Contract Development and Manufacturing Organization (CDMO) that produces native and recombinant bacterial products and provides cGMP manufacturing services. Its offerings include research reagent products (toxins, toxoids, FRET peptides, antibodies, vaccine carrier proteins, adjuvants, and GMP lipopolysaccharides) and CDMO services covering process development, GMP manufacturing for Phase I and II clinical trials, and QC analytical testing for live biotherapeutics, bacterial toxins, polysaccharides, and recombinant proteins.

Product overview

List Biological Laboratories (List Labs) is a microbial Contract Development and Manufacturing Organization (CDMO) offering a comprehensive portfolio of bacterial products and services. The company operates as a single integrated platform with two main offerings: research reagents (nearly 100 products) and CDMO services for clinical manufacturing. Research reagent products include Bacterial Toxins, Toxoids, FRET Peptides/Native Substrates, Vaccine Carrier Proteins & Adjuvants, Antibodies, and GMP Products. CDMO services span Live Biotherapeutics (LBPs), Bacterial Toxins, Bacterial Polysaccharides, Recombinant Proteins, Custom Services, Process Development, GMP Manufacturing (Phase I & II), and QC Analytical Testing. The company supports pharmaceutical companies, biotechs, startups, and government organizations with capabilities from early-stage process development through Phase I & II clinical supply.

Differentiator

Problem solved

Functional benefit

Products and services

• Live Biotherapeutic Products (LBPs) CDMO Service Contract development and manufacturing of live biotherapeutic products for microbiome-based therapeutics, supporting Phase I and II clinical trials with capabilities for aerobic, anaerobic, and spore-forming organisms. Designed for pharmaceutical and biotechnology companies developing microbiome therapeutics.
• Bacterial Toxins CDMO Service Manufacturing of reagent-grade and GMP bacterial toxin products for clinical trials, including process development and purification services for bacterial proteins. Targets pharmaceutical and biotech customers developing bacterial toxin-based therapeutics.
• Bacterial Polysaccharides CDMO Service Production of polysaccharides at reagent grade and GMP manufacturing for vaccines and inflammatory challenge models, including lipopolysaccharides (LPS). Designed for vaccine developers and inflammatory disease researchers.
• Recombinant Proteins CDMO Service Recombinant protein production for R&D and Phase I and II clinical trials using bacterial or mammalian expression systems, including E. coli and B. subtilis. For pharmaceutical and biotech customers needing recombinant protein supply.
• Custom Bacterial Product Services Custom reagent or GMP-grade bacterial product fills, custom batches of research reagents, and customized project management for bacterial manufacturing projects. Tailored to client specifications.
• cGMP Process Development cGMP process development services including cell bank preservation, inoculum optimization, media optimization, fermentation, harvesting, purification, lyophilization, and analytical method development. Provided to clinical-stage pharmaceutical and biotech clients.
• cGMP Manufacturing (Phase I & II) cGMP drug substance and drug product manufacturing for Phase I and II clinical trials, including Master Cell Banks, Working Cell Banks, placebos, and biological intermediates. For clients requiring clinical supply of bacterial-derived candidates.
• QC Analytical Testing Quality control and analytical testing services including ELISA, viability assays, HPLC, stability testing, Western Blot, endotoxin testing, and LBP-specific testing. Supports CDMO clients and internal release of bacterial products.
• Research Reagent Bacterial Toxins Catalog product portfolio of nearly 100 research reagent products including bacterial toxins such as anthrax, botulinum, C. difficile, cholera, clostridial, diphtheria/CRM, enterotoxin, lipopolysaccharides (LPS), Pasteurella multocida, pertussis, shiga, and tetanus toxins for bacterial research.
• Research Reagent Toxoids Inactivated toxin products including botulinum toxoids, C. difficile toxoids, diphtheria toxoid, tetanus toxoid, and enterotoxin toxoid for research applications.
• FRET Peptides and Native Substrates (SNAPtide, VAMPtide, SYNTAXtide, MAPKKide) Fluorescently labeled substrates for detecting toxin activity, including SNAPtide (proprietary patented technology, US 6,504,006 and US 61/252,675), VAMPtide, SYNTAXtide, and MAPKKide products. Includes substrates and receptors for botulinum neurotoxin and anthrax lethal factor research.
• Vaccine Carrier Proteins and Adjuvants Products including cholera toxin B subunit, diphtheria proteins, pertussis toxin mutant, tetanus toxoid, lipid A, and lipopolysaccharides (LPS) for vaccine and adjuvant development research.
• Research Reagent Antibodies Antibody products including anti-anthrax toxins, anti-botulinum neurotoxin, anti-C. difficile toxins, anti-cholera B subunit (goat), anti-exotoxin A (goat), and anti-shiga toxin for bacterial research.
• GMP Products (GMP Lipopolysaccharides) cGMP-grade bacterial products including GMP lipopolysaccharides (LPS) for clinical and commercial use. Targeted at pharmaceutical and biotech customers requiring clinical/commercial-grade bacterial raw materials.

Quantifiable outcome

• Manufacturing capabilities for 100+ bacterial product types
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• SZABO-SCANDIC HandelsGmbHcoreChannel Partner/ Reseller/ Distributor · 7 August 2024Distribution agreement for Austria market. SZABO-SCANDIC serves as the exclusive distributor for List Labs products in Austria, expanding the company's European distribution network.
• BetterLife PharmacoreStrategic or Co-development PartnerManufacturing agreement for interferon alpha 2b production. BetterLife Pharma is developing Altum Pharmaceuticals' interferon alpha 2b product, with List Labs providing manufacturing services.
• List BiotherapeuticscoreOthersWholly-owned subsidiary facility located in Fishers, Indiana. This 26,000 sq ft GMP manufacturing facility focuses on live biotherapeutic products and microbiome therapeutics manufacturing.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Bacthera: Bacthera is the Lonza–Chr. Hansen joint venture launched specifically for Live Biotherapeutic Product contract development and manufacturing. It is the most direct comparable to List Labs' LBP and microbial CDMO offering and competes for the same clinical-stage microbiome programs.
• Arranta Bio: Arranta Bio is a CDMO purpose-built for microbiome and live biotherapeutic products, offering fermentation, encapsulation, and analytical services. It directly overlaps with List Labs' LBP CDMO services for both early-stage and clinical-phase microbiome sponsors.
• Vibalogics: Vibalogics is a virotherapy and microbial biologics CDMO with bacterial fermentation and GMP capabilities. It overlaps with List Labs' bacterial and recombinant protein CDMO services and competes for clinical-phase bacterial vaccine and therapeutic projects.
• Wacker Biotech: Wacker Biotech is a microbial CDMO specializing in E. coli-based and other bacterial expression systems for pharmaceutical proteins and live biotherapeutics. It competes directly with List Labs for clinical-phase bacterial expression and recombinant protein contracts.

Emerging players

• GenScript ProBio: GenScript ProBio is the CDMO arm of GenScript with microbial fermentation, plasmid, and viral vector capabilities. It serves the same biotech sponsor base as List Labs and is rapidly expanding into live biotherapeutic and bacterial protein manufacturing services.

Broad incumbents

• Lonza: Lonza is a global, full-service biologics CDMO with established microbial fermentation, mammalian cell culture, and active pharmaceutical ingredient manufacturing. Its Bacthera JV and broader microbial capabilities make it a wide competitive incumbent for List Labs' target sponsors.
• AGC Biologics: AGC Biologics is a global CDMO offering microbial and mammalian biologics manufacturing across clinical and commercial scales. It is a comparable for sponsors considering List Labs versus a broader CDMO with Phase III/commercial optionality.
• Samsung Biologics: Samsung Biologics is a large, publicly listed Korean CDMO and direct geographic peer (same Korean ecosystem as List Labs' parent). Its scale and full-spectrum clinical-to-commercial services overlap with the upper end of List Labs' addressable market.
• WuXi Biologics: WuXi Biologics is one of the largest global biologics CDMOs with end-to-end clinical and commercial manufacturing. It overlaps with List Labs' clinical-phase offerings and competes for biotech sponsors evaluating microbial CDMOs globally.
• Eurofins CDMO (Eurofins Discovery / Biopharma Product Testing): Eurofins' CDMO and biopharma product testing services cover QC/analytical testing, viral vaccine manufacturing, and microbial services. It overlaps with List Labs' QC Analytical Testing service line and competes for testing budgets alongside full manufacturing contracts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/listlabs
• YouTubeyoutube.com/channel/UCkjxRJLYX_hBwRl-TA6ewJw
• Facebookfacebook.com/ListLabs
• LinkedInlinkedin.com/company/list-biological-laboratories-inc-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about List Biological Laboratories